The April 2023 catch-up price reductions are causing significant concern across the biopharmaceutical sector and while the framework has captured many recently reimbursed brands it has the appearance of targeting one particular group of medicines. …
The appearance of a pricing policy targeting one group of medicines
August 19, 2022 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
EU backs Australian-led consortium with up to $250m to advance next-generation influenza vaccines
February 26, 2026 - - Latest News -
United front forms across Asia Pacific to change the future of Pulmonary Arterial Hypertension
February 26, 2026 - - Latest News -
There are, in effect, two Pharmaceutical Benefits Schemes operating in Australia today
February 26, 2026 - - Latest News -
Reading the room on reform might mean following the Budget message
February 25, 2026 - - Latest News -
Weight-loss medicines approved in New Zealand, and recommended for funding, but pathway remains unclear
February 25, 2026 - -
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum
February 25, 2026 - - Australian Biotech -
Acrux returns to profit as product launches and strategic reset drive revenue growth
February 25, 2026 - - Latest News